Meghan Markle is returning to acting for the first time in seven years for the upcoming movie Close Personal Friends, which ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s Verzenio has proven it can extend patients’ lives in the indication. Verzenio ...

Finally, another episode of Blind Date has graced our screens. Despite wrapping his U.S. tour just a few weeks ago, Conan Gray arrived looking fab, refreshed, and ready for a lovely pasta dinner with ...

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition aligns Lilly's ...

Eli Lilly (NYSE:LLY) on Friday reported plans to acquire Adverum Biotechnologies (NASDAQ:ADVM) and its lead gene therapy candidate, Ixo-vec, sending Adverum shares soaring in premarket trading. Under ...

Oct 24 (Reuters) - Eli Lilly (LLY.N), opens new tab announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for alopecia and eczema. The company ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Morning, ...

Trump says Ozempic prices will be 'much lower' Novo shares fell to almost three week low Shares in rivals Eli Lilly and Zealand Pharma also drop Although Ozempic is approved to treat diabetes, it has ...

Despite the company's run in recent years, it's not too late to buy. Even with headwinds it has encountered this year, the drugmaker is arguably one of the top stocks in its industry to buy right now.

Eli Lilly and Company (NYSE:LLY) shares are trading lower Friday, among other GLP-1 drug manufacturers, following President Donald Trump‘s comments that fat-loss drugs will be a lot lower in price.